🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yujie Cui

Fifth Hospital of Shijiazhuang

ORCID: 0000-0001-9466-9853

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer”.

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03470-y

N/A

0.809DataRank · unranked

22 citations

Weihua Guo, Susan E. Yost, Xuan Ge, Jin Sun Lee, Paul Frankel +12 more

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

The Oncologist(2023)10.1093/oncolo/oyad026

N/A

0.580DataRank · unranked

14 citations

Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang +10 more

Elevated high-density lipoprotein cholesterol and adverse outcomes in women with symptoms of ischemic heart disease

American Heart Journal Plus Cardiology Research and Practice(2024)10.1016/j.ahjo.2024.100376

N/A

0DataRank · unranked

5 citations

Yujie Cui, Amer Muhyieddeen, Okezi Obrutu, Janet Wei, Martha Gulati +6 more